天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Home Cart 0 Sign in  

[ CAS No. 94744-50-0 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 94744-50-0
Chemical Structure| 94744-50-0
Structure of 94744-50-0 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 94744-50-0 ]

Related Doc. of [ 94744-50-0 ]

Alternatived Products of [ 94744-50-0 ]
Product Citations

Product Details of [ 94744-50-0 ]

CAS No. :94744-50-0 MDL No. :MFCD00151913
Formula : C19H19NO4 Boiling Point : No data available
Linear Structure Formula :- InChI Key :HOZZVEPRYYCBTO-UHFFFAOYSA-N
M.W : 325.36 Pubchem ID :2756096
Synonyms :

Calculated chemistry of [ 94744-50-0 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 24
Num. arom. heavy atoms : 12
Fraction Csp3 : 0.26
Num. rotatable bonds : 6
Num. H-bond acceptors : 4.0
Num. H-bond donors : 2.0
Molar Refractivity : 90.02
TPSA : 75.63 ?2

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : Yes
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.98 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.26
Log Po/w (XLOGP3) : 3.24
Log Po/w (WLOGP) : 3.39
Log Po/w (MLOGP) : 2.55
Log Po/w (SILICOS-IT) : 2.77
Consensus Log Po/w : 2.84

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.56

Water Solubility

Log S (ESOL) : -3.87
Solubility : 0.0436 mg/ml ; 0.000134 mol/l
Class : Soluble
Log S (Ali) : -4.5
Solubility : 0.0103 mg/ml ; 0.0000315 mol/l
Class : Moderately soluble
Log S (SILICOS-IT) : -5.27
Solubility : 0.00173 mg/ml ; 0.00000532 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 0.0
Synthetic accessibility : 3.46

Safety of [ 94744-50-0 ]

Signal Word:Warning Class:
Precautionary Statements:P261-P305+P351+P338 UN#:
Hazard Statements:H302-H315-H319-H335 Packing Group:
GHS Pictogram:

Application In Synthesis of [ 94744-50-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 94744-50-0 ]

[ 94744-50-0 ] Synthesis Path-Downstream   1~10

  • 1
  • [ 918663-78-2 ]
  • [ 35661-60-0 ]
  • [ 96402-49-2 ]
  • [ 94744-50-0 ]
  • [ 1187754-67-1 ]
  • 2
  • [ 918663-78-2 ]
  • [ 35737-15-6 ]
  • [ 96402-49-2 ]
  • [ 94744-50-0 ]
  • [ 1187754-66-0 ]
  • 3
  • [ 159610-89-6 ]
  • [ 68858-20-8 ]
  • [ 71989-38-3 ]
  • [ 71989-26-9 ]
  • [ 77284-32-3 ]
  • [ 94744-50-0 ]
  • N,N'-bis(tert-butyloxycarbonyl)-L-lysine dicyclohexylamine salt [ No CAS ]
  • [ 198561-07-8 ]
  • [ 1443329-49-4 ]
  • 4
  • polyethylene glycol polyamide resin [ No CAS ]
  • [ 29022-11-5 ]
  • [ 35661-60-0 ]
  • [ 35661-39-3 ]
  • Palm-γGlu-γGlu-OSu [ No CAS ]
  • [ 71989-31-6 ]
  • [ 35661-40-6 ]
  • [ 71989-33-8 ]
  • [ 71989-14-5 ]
  • [ 71989-18-9 ]
  • [ 71989-23-6 ]
  • [ 71989-26-9 ]
  • [ 71989-35-0 ]
  • [ 132327-80-1 ]
  • [ 71989-33-8 ]
  • [ 94744-50-0 ]
  • [ 32926-43-5 ]
  • [ 143824-78-6 ]
  • [ 204777-78-6 ]
  • Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine [ No CAS ]
  • H-dSer-Q-G-T-F-T-S-D-L-S-K-Q-K((S)-4-carboxy-4-((S)-4-carboxy-4-hexadecanoylamino-butyrylamino)butyryl)-D-E-E-A-A-R-L-F-I-E-W-L-Aib-A-G-G-P-S-S-G-A-P-P-P-S-NH2 [ No CAS ]
YieldReaction ConditionsOperation in experiment
The solid phase synthesis as described in Methods was carried out on Novabiochem Rink-Amide resin (4-(2',4'-Dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetamido- norleucylaminomethyl resin), 100-200 mesh, loading of 0.23 mmol/g. The Fmoc- synthesis strategy was applied with HBTU/DIPEA-activation. In position 14 Fmoc- Lys(ivDde)-OH and in position 1 Boc-His(Trt)-OH were used in the solid phase synthesis protocol. The ivDde-group was cleaved from the peptide on resin according to literature (S.R. Chhabra et al., Tetrahedron Lett. 39, (1998), 1603). Hereafter Palm- yGlu-yGlu-OSu was coupled to the liberated amino-group employing DIPEA as base. The peptide was cleaved from the resin with King's cocktail (D. S. King, C. G. Fields, G. B. Fields, Int. J. Peptide Protein Res. 36, 1990, 255-266). The crude product was purified via preparative HPLC on a Waters column (XBridge, BEH130, Prep C18 5muMu) using an acetonitrile/water gradient (both buffers with 0,1 percent TFA). The purified peptide was analysed by LCMS (Method A). Deconvolution of the mass signals found under the peak with retention time 12.61 min revealed the peptide mass 4581 ,5 which is in line with the expected value of 4581 ,1 . Peptide Synthesizer (Protein Technologies Inc) or similar automated synthesizer using standard Fmoc chemistry and HBTU/DIPEA activation. DMF was used as the solvent. Deprotection : 20percent piperidine/DMF for 2 x 2.5 min. Washes: 7 x DMF. Coupling 2:5:10 200 mM AA / 500 mM HBTU / 2M DIPEA in DMF 2 x for 20 min. Washes: 5 x DMF. In cases where a Lys-side-chain was modified, Fmoc-L-Lys(ivDde)-OH or Fmoc-L- Lys(Mmt)-OH was used in the corresponding position. After completion of the synthesis, the ivDde group was removed according to a modified literature procedure (S.R. Chhabra et al., Tetrahedron Lett. 39, (1998), 1603), using 4percent hydrazine hydrate in DMF. The Mmt group was removed by repeated treatment with 1 percent TFA in dichloromethane. The following acylations were carried out by treating the resin with the N-hydroxy succinimide esters of the desired acid or using coupling reagents like HBTU/DIPEA or HOBt/DIC. All the peptides that have been synthesized were cleaved from the resin with King's cleavage cocktail consisting of 82.5percent TFA, 5percent phenol, 5percent water, 5percent thioanisole, 2.5percent EDT The crude peptides were then precipitated in diethyl or diisopropyl ether, centrifuged, and lyophilized. Peptides were analyzed by analytical HPLC and checked by ESI mass spectrometry. Crude peptides were purified by a conventional preparative RP-HPLC purification procedure.
  • 5
  • [ 29022-11-5 ]
  • [ 68858-20-8 ]
  • [ 35661-60-0 ]
  • [ 35661-39-3 ]
  • [ 112883-29-1 ]
  • [ 35661-40-6 ]
  • [ 136083-57-3 ]
  • [ 104091-09-0 ]
  • [ 71989-23-6 ]
  • [ 35737-15-6 ]
  • [ 73731-37-0 ]
  • [ 71989-16-7 ]
  • [ 105047-45-8 ]
  • [ 73724-45-5 ]
  • [ 71989-20-3 ]
  • [ 91000-69-0 ]
  • [ 96402-49-2 ]
  • [ 94744-50-0 ]
  • Y-(α-aminoisobutyroyl)-EGTFTSDYSIYLDKKAQRAFVNWLLA-(α-aminoisobutyroyl)-KYG-(β-(1-naphthyl)-alaninoyl)-LDF-NH2 [ No CAS ]
YieldReaction ConditionsOperation in experiment
Solid phase peptide synthesis was performed on a CEM Liberty Peptide Synthesizer using standard Fmoc chemistry. TentaGel S Ram resin (1 g; 0.25 mmol/g) was swelled in NMP (10 ml) prior to use and transferred between tube and reaction vessel using DCM and NMP. Coupling (0148) An Fmoc-amino acid in NMP/DMF/DCM (1:1:1; 0.2 M; 5 ml) was added to the resin in a CEM Discover microwave unit together with HATU/DMF or COMU/DMF (0.5 M; 2 ml) and DIPEA/NMP (2.0 M; 1 ml). The coupling mixture was heated to 75° C. for 5 min while nitrogen was bubbled through the mixture. The resin was then washed with NMP (4×10 ml). Deprotection (0149) Piperidine/DMF (20percent; 10 ml) was added to the resin for initial deprotection and the mixture was heated by microwaves (30 sec; 40° C.). The reaction vessel was drained and a second portion of piperidine/NMP (20percent; 10 ml) was added and heated (75° C.; 3 min.) again. The resin was then washed with DMF (6×10 ml). Side Chain Acylation (0150) Fmoc-Lys(ivDde)-OH or alternatively another amino acid with an orthogonal side chain protective group was introduced at the position of the acylation. The N-terminal of the peptide backbone was then Boc-protected using Boc2O or alternatively by using a Boc-protected amino acid in the last coupling. While the peptide was still attached to the resin, the orthogonal side chain protective group was selectively cleaved using freshly prepared hydrazine hydrate (2-4percent) in NMP for 2×15 min. The unprotected lysine side chain was first coupled with Fmoc-Glu-OtBu or another spacer amino acid, which was deprotected with piperidine and acylated with a lipophilic moiety using the peptide coupling methodology as described above. Alternatively, the acylation moiety was introduced as a premade building block e.g. Fmoc-Lys(hexadecanoyl-gamma-Glu)-OH where gamm-Glu is the coupling of Glutamic acid through the side-chain. Abbreviations employed are as follows: COMU: 1-[(1-(cyano-2-ethoxy-2-oxoethylideneaminooxy)-dimethylamino-morpholinomethylene)]methanaminium hexaflourophosphate ivDde: 1-(4,4-dimethyl-2,6-dioxocyclohexylidene)3-methyl-butyl Dde: 1-(4,4-dimethyl-2,6-dioxocyclohexylidene)-ethyl DCM: dichloromethane DMF: N,N-dimethylformamide (0151) DIPEA: diisopropylethylamine EtOH: ethanol Et2O: diethyl ether HATU: N-[(dimethylamino)-1H-1,2,3-triazol[4,5-b]pyridine-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide MeCN: acetonitrile NMP: N-methylpyrrolidone (0152) TFA: trifluoroacetic acid TIS: triisopropylsilane Cleavage (0153) The resin was washed with EtOH (3×10 ml) and Et2O (3×10 ml) and dried to constant weight at room temperature (r.t.). The crude peptide was cleaved from the resin by treatment with TFA/TIS/water (95/2.5/2.5; 40 ml, 2 h; r.t.). Most of the TFA was removed at reduced pressure and the crude peptide was precipitated and washed three times with diethylether and dried to constant weight at room temperature. HPLC Purification of the Crude Peptide (0154) The crude peptide was purified to greater than 90percent by preparative reverse phase HPLC using a PerSeptive Biosystems VISION Workstation equipped with a C-18 column (5 cm; 10 mum) and a fraction collector and run at 35 ml/min with a gradient of buffer A (0.1percent TFA, aq.) and buffer B (0.1percent TFA, 90percent MeCN, aq.). Fractions were analyzed by analytical HPLC and MS and relevant fractions were pooled and lyophilized. The final product was characterized by HPLC and MS. (0155) The synthesized compounds are shown in Table 1 and Table 2
  • 6
  • [ 35661-60-0 ]
  • [ 71989-31-6 ]
  • [ 35661-40-6 ]
  • [ 103478-62-2 ]
  • [ 77128-73-5 ]
  • [ 94744-50-0 ]
  • C50H69N7O8 [ No CAS ]
  • 7
  • [ 29022-11-5 ]
  • [ 35661-60-0 ]
  • [ 35661-39-3 ]
  • Palm-γGlu-γGlu-OSu [ No CAS ]
  • [ 71989-31-6 ]
  • [ 35661-40-6 ]
  • [ 71989-33-8 ]
  • [ 71989-14-5 ]
  • [ 71989-18-9 ]
  • [ 71989-23-6 ]
  • [ 71989-26-9 ]
  • [ 71989-35-0 ]
  • [ 35661-38-2 ]
  • [ 132327-80-1 ]
  • [ 109425-51-6 ]
  • [ 94744-50-0 ]
  • [ 32926-43-5 ]
  • [ 143824-78-6 ]
  • [ 159857-60-0 ]
  • Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine [ No CAS ]
  • H-Aib-Q-G-T-F-T-S-D-L-S-K-L-K[gGlu-gGlu-Palm]-E-E-Q-R-Q-Aib-E-F-I-E-W-L-K-A-dAla-G-H-P-S-Aib-K-P-P-P-K-NH2; Aib=alpha-amino-isobutyric acid, gGlu=gamma-glutamate, Palm=palmitoyl [ No CAS ]
YieldReaction ConditionsOperation in experiment
The solid phase synthesis as described in Methods was carried out on Novabiochem Rink-Amide resin (4-(2?,4?-Dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetamido-norleucylaminomethyl resin), 100-200 mesh, loading of 0.43 mmol/g. The Fmoc-synthesis strategy was applied with HBTU/DIPEA-activation. In position 14 Fmoc-Lys(Mmt)-OH and in position 1 Boc-His(Trt)-OH were used in the solid phase synthesis protocol. The Mmt-group was cleaved from the peptide on resin as described in the Methods. Hereafter Palm-gGlu-gGlu-OSu was coupled to the liberated amino-group employing DIPEA as base. The peptide was cleaved from the resin with King's cocktail (D. S. King, C. G. Fields, G. B. Fields, Int. J. Peptide Protein Res. 1990, 36, 255-266). The crude product was purified via preparative HPLC on a Waters column (Sunfire Prep C18 OBD 5 mum 50×150 mm) using an acetonitrile/water gradient (both buffers with 0.1percent TFA). The purified peptide was analysed by LCMS (Method B). (0376) Deconvolution of the mass signals found under the peak with retention time 9.828 min revealed the peptide mass 4894.63 which is in line with the expected value of 4894.64.
  • 8
  • [ 29022-11-5 ]
  • [ 35661-60-0 ]
  • [ 35661-39-3 ]
  • Palm-γGlu-γGlu-OSu [ No CAS ]
  • [ 71989-31-6 ]
  • [ 35661-40-6 ]
  • [ 71989-33-8 ]
  • [ 71989-14-5 ]
  • [ 71989-18-9 ]
  • [ 71989-23-6 ]
  • [ 71989-26-9 ]
  • [ 71989-35-0 ]
  • [ 35661-38-2 ]
  • [ 132327-80-1 ]
  • [ 109425-51-6 ]
  • [ 94744-50-0 ]
  • [ 32926-43-5 ]
  • [ 143824-78-6 ]
  • [ 159857-60-0 ]
  • Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine [ No CAS ]
  • H-Aib-Q-G-T-F-T-S-D-L-S-K-L-K[gGlu-gGlu-Palm]-E-K-Q-R-Q-Aib-E-F-I-E-W-L-K-A-dAla-G-H-P-S-Aib-K-P-P-P-K-NH2; Aib=alpha-amino-isobutyric acid, gGlu=gamma-glutamate, Palm=palmitoyl [ No CAS ]
YieldReaction ConditionsOperation in experiment
The solid phase synthesis as described in Methods was carried out on Novabiochem Rink-Amide resin (4-(2?,4?-Dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetamido-norleucylaminomethyl resin), 100-200 mesh, loading of 0.43 mmol/g. The Fmoc-synthesis strategy was applied with HBTU/DIPEA-activation. In position 14 Fmoc-Lys(Mmt)-OH and in position 1 Boc-His(Trt)-OH were used in the solid phase synthesis protocol. The Mmt-group was cleaved from the peptide on resin as described in the Methods. Hereafter Palm-gGlu-gGlu-OSu was coupled to the liberated amino-group employing DIPEA as base. The peptide was cleaved from the resin with King's cocktail (D. S. King, C. G. Fields, G. B. Fields, Int. J. Peptide Protein Res. 1990, 36, 255-266). The crude product was purified via preparative HPLC on a Waters column (Sunfire Prep C18 OBD 5 mum 50×150 mm) using an acetonitrile/water gradient (both buffers with 0.1percent TFA). The purified peptide was analysed by LCMS (Method B). (0376) Deconvolution of the mass signals found under the peak with retention time 9.828 min revealed the peptide mass 4894.63 which is in line with the expected value of 4894.64. In an analogous way, the other peptides listed in Table 3 were synthesized and characterized.
  • 9
  • [ 29022-11-5 ]
  • [ 35661-60-0 ]
  • [ 35661-39-3 ]
  • Palm-γGlu-γGlu-OSu [ No CAS ]
  • [ 71989-31-6 ]
  • [ 35661-40-6 ]
  • [ 71989-33-8 ]
  • [ 71989-14-5 ]
  • [ 71989-18-9 ]
  • [ 71989-23-6 ]
  • [ 71989-26-9 ]
  • [ 71989-35-0 ]
  • [ 35661-38-2 ]
  • [ 132327-80-1 ]
  • [ 94744-50-0 ]
  • [ 32926-43-5 ]
  • [ 143824-78-6 ]
  • [ 159857-60-0 ]
  • Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine [ No CAS ]
  • H-Aib-Q-G-T-F-T-S-D-L-S-K-L-K[gGlu-gGlu-Palm]-E-K-Q-R-Q-Aib-E-F-I-E-W-L-K-A-dAla-G-P-P-S-Aib-K-P-P-P-K-NH2; Aib=alpha-amino-isobutyric acid, gGlu=gamma-glutamate, Palm=palmitoyl [ No CAS ]
YieldReaction ConditionsOperation in experiment
The solid phase synthesis as described in Methods was carried out on Novabiochem Rink-Amide resin (4-(2?,4?-Dimethoxyphenyl-Fmoc-aminomethyl)-phenoxyacetamido-norleucylaminomethyl resin), 100-200 mesh, loading of 0.43 mmol/g. The Fmoc-synthesis strategy was applied with HBTU/DIPEA-activation. In position 14 Fmoc-Lys(Mmt)-OH and in position 1 Boc-His(Trt)-OH were used in the solid phase synthesis protocol. The Mmt-group was cleaved from the peptide on resin as described in the Methods. Hereafter Palm-gGlu-gGlu-OSu was coupled to the liberated amino-group employing DIPEA as base. The peptide was cleaved from the resin with King's cocktail (D. S. King, C. G. Fields, G. B. Fields, Int. J. Peptide Protein Res. 1990, 36, 255-266). The crude product was purified via preparative HPLC on a Waters column (Sunfire Prep C18 OBD 5 mum 50×150 mm) using an acetonitrile/water gradient (both buffers with 0.1percent TFA). The purified peptide was analysed by LCMS (Method B). (0374) Deconvolution of the mass signals found under the peak with retention time 9.935 min revealed the peptide mass 4853.73 which is in line with the expected value of 4853.67.
  • 10
  • [ 35661-60-0 ]
  • [ 94744-50-0 ]
  • [ 71989-31-6 ]
  • [ 143674-78-6 ]
  • [ 198561-07-8 ]
  • cyclo[D-Pro-D-Leu-Aib-Pgl-D-Leu-Tyr] [ No CAS ]
Recommend Products
Same Skeleton Products

Technical Information

Historical Records

Related Functional Groups of
[ 94744-50-0 ]

Amino Acid Derivatives

Chemical Structure| 1311992-97-8

[ 1311992-97-8 ]

2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-2-allylpent-4-enoic acid

Similarity: 0.91

Chemical Structure| 857478-30-9

[ 857478-30-9 ]

Fmoc-IsoVal-OH

Similarity: 0.91

Chemical Structure| 1231709-22-0

[ 1231709-22-0 ]

(R)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-2-methylbutanoic acid

Similarity: 0.91

Chemical Structure| 288617-71-0

[ 288617-71-0 ]

(S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-2-methylpent-4-enoic acid

Similarity: 0.91

Chemical Structure| 116861-26-8

[ 116861-26-8 ]

Fmoc-D-Ser-OH

Similarity: 0.91

; ;